AnaCardio key facts
as of Oct 2026- Developer of therapeutic drugs designed to improve clinical outcomes in cardiac failure.
- AnaCardio is valued at approximately $292.9M as of Oct 2026, set at its Series B, Sep 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $44.2M across 1 recorded rounds; the latest was Series B in Sep 2026.
- Notable investors include Novo Holdings, Innovestor, Industrifonden, Nordic Mentor Network For Entrepreneurship, Helsinn Healthcare — 13 tracked in total.
- Status: Privately Held (backing).
Valued at $292.9M at its Series B, Sep 2026. Nothing has traded since.
- ·The post-money valuation on its round
- ·The complete investor list: 13 names
- ·Watch AnaCardio: the Monday email on marks, rounds and moves
AnaCardio funding rounds
1 roundsWho backs AnaCardio
13+AnaCardio valuation
AnaCardio was valued at $293 million at its Series B in Sep 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
Recent activity
In the last 90 days, AnaCardio's record added 1 funding round.
How much has AnaCardio raised?
AnaCardio has raised $44.2 million in total; 1 of its rounds is on record. The most recent was a Series B in Sep 2026. 1 of the rounds disclosed a post-money valuation.
AnaCardio investors
13 investors are on record for AnaCardio, including Novo Holdings, Innovestor, Industrifonden and Nordic Mentor Network For Entrepreneurship. The Series B in Sep 2026 drew 9 investors.
About AnaCardio
Developer of therapeutic drugs designed to improve clinical outcomes in cardiac failure. The company's drugs improve the contractility of the heart muscle through a differentiated mechanism using a therapeutic peptide without causing adverse tachycardia, arrhythmia, ischemia, or hypotension, enabling medical professionals to provide safe cardiac output in human heart failure which can potentially improve organ function, quality of life and functional capacity, and reduce the risk of hospitalization and death.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2017
- Employees
- 11
- Website
- anacardio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.